BIOLASE, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-12-06: Form 8-K; Period of report 2019-12-03; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2019-11-19: Form 8-K; Period of report 2019-11-14; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; Details 5.02.
- 2019-11-06: Form 8-K; Period of report 2019-11-06; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2019-11-01: Form 8-K; Period of report 2019-10-28; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-12-06 | 8-K | 2019-12-03 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On December 3, 2019, Biolase, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). | d801789d8k.htm |
| 2019-11-19 | 8-K | 2019-11-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On November 14, 2019, the Board of Directors (the “Board”) of Biolase, Inc. (the “Company”) elected Michael DiTolla to the Board. | d79302d8k.htm |
| 2019-11-06 | 8-K | 2019-11-06 | 2.02 Results of Operations and Financial Condition | 2.02 On November 6, 2019, BIOLASE, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2019. | biol-8k_20191106.htm |
| 2019-11-01 | 8-K | 2019-10-28 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The disclosure set forth in Item 1.01 above is hereby incorporated into this Item 2.03 by reference. | d822504d8k.htm |
| 2019-10-30 | 8-K | 2019-10-24 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders | 1.01 Entry into a Material Definitive Agreement. 3.02 The disclosure set forth in Item 1.01 above under “Private Placement” is hereby incorporated into this Item 3.02 by reference. 3.03 In connection with the completion of the Private Placement, on October 29, 2019, the Company filed the Certificate of Designations, Preferences and Rights of Series E Participating Convertible Preferred Stock of BIOLASE, Inc. (the “Certificate of Designations”) with the Secretary of State of the State of Delaware to establish the terms, rights, obligations and preferences of the Series E Preferred Stock. | d826340d8k.htm |
| 2019-10-25 | 8-K | 2019-10-24 | 7.01 Regulation FD Disclosure | 7.01 On October 24, 2019, BIOLASE, Inc. issued a press release announcing the pricing of an underwritten public offering and concurrent private placement. | d805747d8k.htm |
| 2019-10-21 | 8-K | 2019-10-21 | 2.02 Results of Operations and Financial Condition | 2.02 On October 21, 2019, BIOLASE, Inc. (the “Company”) issued a press release announcing certain unaudited preliminary financial results for the third quarter ended September 30, 2019. | d770124d8k.htm |
| 2019-10-04 | 8-K | 2019-09-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d811851d8k.htm |
| 2019-09-05 | 8-K | 2019-09-05 | 7.01 Regulation FD Disclosure | 7.01 On September 5, 2019, Todd A. Norbe, President and Chief Executive Officer of BIOLASE, Inc. (the “Company”), and John R. Beaver, Executive Vice President and Chief Financial Officer the Company, will hold one-on-one and small group meetings with institutional investors at the 4th Annual Dougherty & Company Institutional Investor Conference. | d791289d8k.htm |
| 2019-08-26 | 8-K | 2019-08-20 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d792012d8k.htm |
| 2019-08-08 | 8-K | 2019-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2019, BIOLASE, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2019. | biol-8k_20190808.htm |
| 2019-05-20 | 8-K | 2019-05-15 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 15, 2019, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”). | d718935d8k.htm |
| 2019-05-09 | 8-K | 2019-05-09 | 2.02 Results of Operations and Financial Condition | 2.02 On May 9, 2019, BIOLASE, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2019. | biol-8k_20190509.htm |
| 2019-03-05 | 8-K | 2019-03-05 | 2.02 Results of Operations and Financial Condition | 2.02 On March 5, 2019, BIOLASE, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2018. | biol-8k_20190305.htm |
| 2019-01-31 | 8-K | 2019-01-25 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d699912d8k.htm |